Blair William & Co. IL Sells 4,318 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Blair William & Co. IL decreased its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 25.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,517 shares of the medical instruments supplier's stock after selling 4,318 shares during the period. Blair William & Co. IL's holdings in Merit Medical Systems were worth $1,211,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in MMSI. NewSquare Capital LLC purchased a new stake in Merit Medical Systems in the fourth quarter worth approximately $32,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Merit Medical Systems in the 4th quarter worth approximately $52,000. Smartleaf Asset Management LLC boosted its stake in shares of Merit Medical Systems by 237.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,388 shares of the medical instruments supplier's stock valued at $134,000 after purchasing an additional 977 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Merit Medical Systems by 14.7% during the 4th quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier's stock valued at $144,000 after purchasing an additional 191 shares during the last quarter. Finally, TD Private Client Wealth LLC lifted its stake in Merit Medical Systems by 13.9% in the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier's stock worth $171,000 after purchasing an additional 211 shares during the last quarter. Hedge funds and other institutional investors own 99.66% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Merit Medical Systems news, CEO Fred P. Lampropoulos sold 31,320 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the completion of the transaction, the chief executive officer now owns 1,086,028 shares of the company's stock, valued at approximately $112,794,868.08. This trade represents a 2.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Stephen C. Evans sold 5,000 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $105.31, for a total transaction of $526,550.00. Following the completion of the sale, the director now directly owns 4,657 shares in the company, valued at $490,428.67. This represents a 51.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,132 shares of company stock worth $11,139,521. Company insiders own 3.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MMSI. JPMorgan Chase & Co. began coverage on Merit Medical Systems in a research report on Friday, March 28th. They set an "overweight" rating and a $120.00 price target on the stock. Barrington Research decreased their target price on shares of Merit Medical Systems from $115.00 to $111.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Raymond James upped their price target on shares of Merit Medical Systems from $105.00 to $110.00 and gave the company an "outperform" rating in a report on Tuesday, December 31st. Wells Fargo & Company cut their price target on shares of Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Finally, Needham & Company LLC decreased their price objective on shares of Merit Medical Systems from $122.00 to $116.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $111.70.

Merit Medical Systems Trading Up 0.0 %

Shares of NASDAQ MMSI traded up $0.01 during midday trading on Monday, hitting $92.51. 1,587,709 shares of the company traded hands, compared to its average volume of 467,087. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. Merit Medical Systems, Inc. has a 12-month low of $70.70 and a 12-month high of $111.45. The stock has a 50-day moving average price of $103.92 and a 200 day moving average price of $101.19. The firm has a market cap of $5.46 billion, a P/E ratio of 45.35, a P/E/G ratio of 2.34 and a beta of 0.85.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.